Cambrium, a Berlin, Germany-based synthetic biology startup, raised €8M in Seed funding.
The round was led by Essential Capital, along with SNR, Valor Equity Partners, and HOF Capital.
The company intends to use the funds to translate the early successes of NovaColl™ into lasting impact, as its manufacturing and commercial activities scale towards full replacement of traditional animal-derived collagen. The funding will also accelerate the its product pipeline, with molecules for new applications and industries to be launched within the next two years.
Led by CEO Mitchell Duffy, Cambrium designs, scales and manufactures novel molecular building blocks for use in personal care, fashion, and beyond. Its platform is empowered by converging advances in AI, automation, and synthetic biology, allowing for the development of innovative biomolecules for the above consumer applications.
Cambrium has raised €11M to date, with prior funding from Merantix.
FinSMEs
31/10/2023